Sartorius Stedim Biotech supports bioprocess development with new Innovation Centre

Published: 22-Nov-2024

The Massachusetts, US-based Centre for Bioprocess Innovation is a collaborative space designed to develop and optimise biomanufacturing processes

Sartorius Stedim Biotech, has officially opened its new Centre for Bioprocess Innovation in Massachusetts, US. 

The facility, situated in the city of Marlborough, has been specifically designed to encourage co-development and collaboration between Sartorius' customers and external partners.

63,000 sqft of the space at this site is dedicated to research and service laboratories, facilities for customer demonstrations and training blocks. 

At the site, Sartorius' team of experts will be able to advise customers on process development, validation and optimisation for advanced therapeutic indications such as cell and gene therapies.

According to Sartorius, its new hub will be able to accomodate more than 120 bioprocessing experts at full capacity — with 50 currently operating there. 

CEO of Sartorius Stedim Biotech, René Fáber, commented: ”Cell and gene therapies and other novel treatments offer promising solutions for patients with previously incurable diseases. However, these modalities are still in their infancy and often require the development of new manufacturing processes, in order to become more efficient and less costly."

"This cutting-edge innovation center enables us to leverage our bioprocessing tools and workflows expertise, ultimately accelerating and simplifying our customers’ path to clinical trials,”

 

Looking ahead to 2025

Sartorius has previously expanded its presence in the Massachusetts area through the acquisition of Marlborough-based WaterSep BioSeparations in 2022.

The company has also opened a Bioprocess Equipment Customer Interaction Centre, which is situated in close proximity to the new Bioprocess Innovation Centre.

Following on from these investments into the area, Sartorius will add two multi-modality GMP suites in 2025, which are designed to further support process development projects into early-stage clinical production. 

This comes as the company invests further into its next-generation therapeutic process development capabilities. 

”The Greater Boston area is a global hub for the biotechnology and life science industries, offering access to world-renowned academic institutions, research facilities and a skilled workforce." said Maurice Phelan, President of Sartorius North America.

”Massachusetts is the global epicenter of life sciences because of companies like Sartorius,” said Yvonne Hao, Massachusetts Secretary of Economic Development. “This new centre will serve as a hub that encourages open collaboration and creates comprehensive research pathways for experts." 

 

You may also like